On the other hand, a high 10-year OS rate was achieved among patients with KIT exon 11 deletion/indel mutation with 3-year adjuvant imatinib and with the subsequent treatments administered after GIST recurrence. This evidence concerns the gene KIT and gastrointestinal stromal tumor.